Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
2009-017171-13Phase 2Completed
- Sponsor
- University College London
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Saracatinib + weekly paclitaxel with Placebo + weekly paclitaxel (2 arms). Primary endpoint: 6-month progression-free survival rate. Started Aug 2010; status: completed.
02
Drugs
saracatinibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2009-017171-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017171-13.